First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast CancerGideon M. Blumenthal, Richard Pazdur, Nancy S. Scher et al.|Clinical Cancer Research|2013Cited by 120
Abstract 3900: Nuclear c-REL displaces p73 in partnering with DNp63 to suppress p21 expression and promote proliferation in head and neck cancerHai Lü, Carter Van Waes, Xinping Yang et al.|Cancer Research|2010Cited by 0